Medios AG
10.18
EUR
-0.20
(-1.93%)
ISIN
DE000A1MMCC8
Return %
Stock
S&P 500
1Y
-20.59
14.20
3Y
-29.01
81.12
5Y
-72.85
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Thomas Meier
- Full Time Employees
- 982
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Heidestrasse 9 Berlin BE Germany 10557
- IPO Date
- Jan 1, 1999
- Website
- medios.ag
- Similar Companies
- Business
- Medios AG is a leading European specialty pharmaceutical company focused on advancing individualized medicine through the compounding of patient-specific therapies and the supply of specialty pharmaceutical solutions. The company manufactures and supplies a broad portfolio of pharmaceuticals addressing complex and chronic conditions, with a strong focus on therapeutic areas including oncology, neurology, autoimmune diseases, ophthalmology, infectious diseases, and hemophilia. It operates six GMP-certified manufacturing facilities, four distribution sites, and its own blistering center, positioning itself as the largest pharmaceutical supplier and compounder of patient-specific therapies in Germany and expanding its footprint in Europe. Medios serves pharmacies, specialist medical practices, hospitals, and pharmaceutical companies, delivering innovative treatments and precision medicines tailored to individual patients. In recent developments, Medios completed the acquisition of Ceban Pharmaceuticals B.V. in 2024, enhancing its manufacturing capabilities and operational efficiency while expanding its geographic reach to Belgium, the Netherlands, and Spain. This acquisition bolsters Medios' network of over 850 partner pharmacies in Germany and supports its strategic vision of building an international network of pharmaceutical compounding facilities focused on personalized medicine. In 2025, Medios has accelerated growth with dynamic revenue increases and significant improvements in earnings, alongside executing a public share buyback program. The company also appointed Thomas Meier as its new CEO in 2025, signaling a leadership transition aligned with its growth strategy. Medios AG operates primarily through three business segments covering the development, manufacturing, and supply of specialty pharmaceutical products, including formulation, manual and aseptic filling, labeling, and blister packaging services for complex therapies. Its products and services cater to highly specialized therapeutic areas that require patient-specific formulations. The company maintains a strong presence across Germany, Belgium, the Netherlands, and Spain and is listed on the Frankfurt Stock Exchange (Prime Standard). Founded in 1998 and headquartered in Berlin, Medios AG has established itself as a key player in the specialty pharma industry by integrating pharmaceutical supply with advanced compounding services, focusing on individualized medicine solutions. The comprehensive product offering includes specialty pharmaceuticals for oncology, neurology, autoimmune diseases, infectious diseases, ophthalmology, and hemophilia, supported by services such as development, formulation, manual and aseptic filling, labeling, and packaging. The company’s recent strategic expansions and operational initiatives reinforce its position as a leading specialty pharma provider in Europe, dedicated to enhancing treatment outcomes through personalized medicine innovations. Medios AG's continuous evolution, including acquisitions and leadership changes, drives its strategy to lead the specialty pharmaceutical market with a focus on patient-centric and precision therapies across multiple European markets, operating from its Berlin headquarters with a growing regional footprint and an innovative product and service portfolio.